CytoDyn
1111 Main Street
Suite 660
Vancouver
Washington
98660
United States
Website: http://www.cytodyn.com/
308 articles about CytoDyn
-
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
12/3/2019
First metastatic triple-negative breast cancer patient showed no detectable circulating tumor cells (CTC) or putative metastatic tumor cells (EMTs) in the peripheral blood. Further, a significant reduction in CCR5 expression was demonstrated on cancer-associated cells after eight weeks of treatment with leronlimab
-
CytoDyn Reports Strong Positive Preclinical Data to Demonstrate Potential of Leronlimab in Treating Nonalcoholic Fatty Liver Disease (NAFLD) in Humanized Mouse Model
11/21/2019
New preclinical data using a humanized mouse model confirms and expands on the potential use of leronlimab in treating this inflammatory syndrome, a common precursor to NASH
-
CytoDyn Engages LifeSci Public Relations as Communications Partner
11/18/2019
LifeSci to develop and execute comprehensive corporate communications and public relations programs
-
Clinical Catch-Up: November 11-15
11/18/2019
It was a busy week for clinical trial announcements. Here’s a look. -
Clinical Catch-Up: September 2-8
9/9/2019
Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting. -
CytoDyn Announces Major Discovery for its Monotherapy Indication
6/18/2019
CytoDyn and IncellDx Report the Successful Development and Validation of an Assay to Assess the Responders for Monotherapy HIV Patients
-
CytoDyn and Samsung BioLogics Formalize Manufacturing Partnership
5/30/2019
CytoDyn Inc., a late stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications and Samsung BioLogics met at the Samsung BioLogics Songdo headquarters for an official signing ceremony of the manufacturing agreement with Samsung BioLogics that was previously announced on April 2, 2019.
-
CytoDyn Reaches Historical Milestone, Submits First of Three Sections of BLA to FDA for Leronlimab (PRO 140) as a Combination Therapy for HIV
3/18/2019
CytoDyn Inc., a late stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that it has filed with the U.S. Food and Drug Administration the non-clinical portion of its Biologics License Application using the FDA’s Rolling Review process.
-
CytoDyn Announces Strong Preclinical Results Using PRO 140 in Human Colon Carcinoma
8/15/2018
CytoDyn will file an IND, along with a proof-of-concept protocol for colon cancer
-
CytoDyn Appoints Michael A. Klump to Board of Directors
8/13/2018
CytoDyn Inc. announces that Michael A. Klump, President and Chief Executive Officer of Argonne Capital Group, has joined the CytoDyn Board of Directors.
-
CytoDyn Announces Significantly Improved Response Rate at Higher Dose of PRO 140 in HIV Phase 3 Monotherapy Trial
7/30/2018
Response rate increases from 40% at 350 mg dose to approximately 70% at 525 mg
-
CytoDyn to Present at Singular Summer Solstice 2018 Conference on July 19
7/17/2018
CytoDyn Inc. announces that Nader Pourhassan, Ph.D., President and CEO, will present at the Singular Research Summer Solstice 2018 Conference on Thursday, July 19, at 2:50 p.m. Eastern time
-
CytoDyn Announces Positive Results from Completed Pivotal PRO 140 HIV Combination Trial
7/16/2018
CytoDyn Inc. announces that approximately 81% of patients who completed the 25-week CD02 pivotal trial with PRO 140 in combination with existing highly active antiretroviral therapy (HAART) showed viral load suppression with plasma HIV-1 RNA viral load of less than 50 copies/mL.
-
CytoDyn to Expand Strategic Focus with PRO 140 to Cancer and Immunologic Disorders
7/12/2018
Announces non-binding Letter of Intent to acquire CCR5-focused cancer company ProstaGene LLC
-
CytoDyn Announces Leadership Changes to Align with Expanded Focus of PRO 140 to Cancer and Immunological Disorders
7/12/2018
CytoDyn Inc. announces leadership changes that align with the strategic expansion of its focus with PRO 140 to cancer and immunological disorders, separately announced today.
-
CytoDyn Announces Productive Pre-BLA Meeting with FDA for PRO 140 Combination Therapy
6/22/2018
Rolling BLA Submission Starting as Early as the End of 2018
-
CytoDyn Provides Update on Phase 2 Clinical Trial with PRO 140 in GvHD
6/20/2018
Patient enrollment proceeding under amended protocol
-
CytoDyn Provides Update On PRO 140 Combination Therapy Pivotal Trial In HIV Patients Following Constructive Meeting With FDA
10/13/2017
-
CytoDyn Receives Orphan Drug Designation For PRO 140 For Prevention Of Graft Versus Host Disease
10/5/2017
-
CytoDyn Provides Further Update On PRO 140 Pivotal Combination Therapy Trial In Patients With HIV
9/6/2017